Your browser doesn't support javascript.
loading
Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin.
Mueller, Silke C; Uehleke, Bernhard; Woehling, Heike; Petzsch, Michael; Majcher-Peszynska, Jolanta; Hehl, Eva-Maria; Sievers, Hartwig; Frank, Bruno; Riethling, Anne-Kathrin; Drewelow, Bernd.
Afiliação
  • Mueller SC; Center of Pharmacology and Toxicology, Institute of Clinical Pharmacology, University of Rostock, Rostock, Germany. silke.mueller@med.uni-rostock.de
Clin Pharmacol Ther ; 75(6): 546-57, 2004 Jun.
Article em En | MEDLINE | ID: mdl-15179409
ABSTRACT
BACKGROUND AND

OBJECTIVE:

St John's wort preparations vary in composition, main constituents, formulation, and daily dose administered. The aim of the study was to evaluate the possible pharmacokinetic interaction of marketed St John's wort formulations and doses with digoxin.

METHODS:

A randomized, placebo-controlled, parallel-group study was performed in 96 healthy volunteers in 3 study parts. A 7-day loading phase with digoxin was followed by 14 days of comedication with placebo or one of 10 St John's wort products varying in dose and formulation. The pharmacokinetics of digoxin was determined before comedication and on day 14 of comedication.

RESULTS:

Comedication comprised traditionally used Hypericum products; 2 g powder without hyperforin, tea, juice, oil extract, and placebo had no significant interaction with digoxin nor did hyperforin-free extract (Ze 117) or low daily doses of hyperforin-containing Hypericum powder (1 g, 0.5 g). However, comedication with the high-dose hyperforin-rich extract LI 160 resulted in a reduction of digoxin area under the curve from time 0 to 24 hours (AUC(0-24)) of -24.8% (95% confidence interval [CI], -28.3 to -21.3), a reduction in digoxin maximal plasma concentration (C(max)) of -37% (95% CI, -42 to -32), and a reduction in digoxin plasma concentration at 24 hours after previous dosing (C(trough)) of -19% (95% CI, -27 to -11). Comedication with 4 g Hypericum powder with comparable hyperforin content resulted in a reduction in digoxin AUC(0-24) of -26.6% (95% CI, -37.3 to -15.9), a reduction in digoxin C(max) of -38% (95% CI, -48 to -18), and a reduction in digoxin C(trough) of -19% (95% CI, -27 to -10). Two grams of Hypericum powder with half the hyperforin content resulted in a less prominent reduction in AUC(0-24) of -17.7% (95% CI, -21.6 to -13.7), C(max) (-21%; 95% CI, -40 to -2), and C(trough) (-13%; 95% CI, -21 to -5).

CONCLUSIONS:

The interaction of St John's wort and digoxin varies within St John's wort preparations and doses and seems to be correlated with the dose, particularly of hyperforin.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Hypericum / Digoxina Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2004 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Hypericum / Digoxina Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2004 Tipo de documento: Article